SCHEMBL2064590

SCHEMBL2064590

CCOC(=O)CNS(=O)(=O)c1ccc(-c2noc(-c3cc(C)c(CN(CC)CC)s3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 7/20 0.41
S1PR3 Q99500 6/20 0.41
ALDH1A1 P00352 3/20 0.39
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
S1PR5 Q9H228 1/20 0.38
RARA P10276 1/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HDAC4 P56524 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2064962 0.91 RARA (0.41) S1PR1S1PR3MMP2MMP9MMP8
SCHEMBL2064418 0.86 HDAC4 (0.43) S1PR1S1PR3MMP2MMP9MMP8
SCHEMBL2064521 0.85 MCHR1 (0.45) S1PR1S1PR3S1PR5RARARARB
SCHEMBL2063900 0.84 PIK3CD (0.42) S1PR1S1PR3ALDH1A1MMP2MMP9
SCHEMBL2064694 0.83 S1PR1 (0.40) S1PR1S1PR3MMP2MMP9MMP8
SCHEMBL2064853 0.82 RARA (0.46) S1PR1S1PR3ALDH1A1S1PR5RARA
SCHEMBL2064223 0.79 RARA (0.59) S1PR1S1PR3RARARARBRARG
SCHEMBL2066234 0.78 S1PR1 (0.45) S1PR1S1PR3S1PR5RARARARB
SCHEMBL2065252 0.77 MCHR1 (0.47) S1PR1S1PR3S1PR5RARARARB
SCHEMBL2065809 0.77 S1PR1 (0.40) S1PR1S1PR3ALDH1A1S1PR5RARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222667-B1 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2013-02-20 EP disclosed
US-8148410-B2 Thiophene derivatives as agonists of S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-03 US disclosed
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2010-10-14 US disclosed
EP-2222667-A2 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 Actelion Pharmaceuticals Ltd. (CH) 2010-09-01 EP disclosed
WO-2009074950-A2 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 S1PR1, S1PR3, S1PR5 S1PR1 1/4885S1PR3 2/4885ALDH1A1 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.